Mebeverine Tablets

Mebeverine is an antispasmodic — a medicine designed to relax the smooth muscle in the wall of the intestine. To understand what that means, picture the gut as a long muscular tube. The walls of that tube contain a thin layer of smooth muscle that contracts in coordinated waves to push food and waste through your digestive system. In irritable bowel syndrome (IBS), those muscle contractions can become exaggerated, irregular, and uncomfortable — the gut wall goes into spasm rather than gentle waves, producing the cramping pain that IBS sufferers know well. Mebeverine works directly on that smooth muscle, persuading it to relax. The clever part of how it does this is that it eases the spasmodic contractions specifically without switching off the normal background movement of the gut, which means you get pain relief without becoming bloated or sluggish.

The standard adult regimen is 135 mg three times a day, taken about 20 minutes before each main meal — breakfast, lunch, and dinner. There's also a modified-release version, marketed in the UK as Colofac MR, which delivers a slow, steady 200 mg twice daily, also taken 20 minutes before meals. The pre-meal timing isn't arbitrary. IBS pain is often triggered by eating, because food entering the gut activates the gastrocolic reflex — a normal reflex that ramps up gut motility after meals. In someone with IBS, that ramp-up is exaggerated and tips the gut into spasm. Taking mebeverine 20 minutes beforehand allows it to start working on the gut muscle just as the food is arriving, blunting the spasm before it can begin. Take the tablets with a little water and don't crush or chew them — the modified-release capsule in particular relies on its coating to release the medicine slowly across the day.

Some people feel a useful effect within the first few days, particularly on post-meal cramping. Others notice change more gradually over two to four weeks of regular use. Mebeverine isn't a painkiller in the conventional sense — it doesn't dull pain like paracetamol or ibuprofen does — and it works best when the gut is being exposed to it consistently before meals. So a fair trial of mebeverine usually means taking it three times a day, every day, for at least a few weeks, before deciding whether it's helping. If you've been taking it irregularly or only when symptoms strike, that may be why it doesn't seem to be making much difference.

There's no fixed time limit. Mebeverine is generally considered safe for long-term use because it doesn't accumulate in the body, doesn't have anticholinergic side effects, and isn't habit-forming. Many people take it for months or even years through periods when their IBS is active, then taper off or stop during quieter spells, then return to it during flares. Some take it as needed when they know they're heading into a stressful or food-triggering situation; others take it daily as standing background treatment. A reasonable approach, in conversation with your prescriber, is to take it consistently for several weeks during a flare-up, then review whether it's still helping — and either continue, reduce to as-needed use, or stop altogether.

No. Mebeverine doesn't have any habit-forming or dependence-producing properties. It works on smooth muscle in the gut, not on the brain's reward or stress circuits, so there's no craving when you stop and no escalating dose required to maintain the effect. Some people find that symptoms return when they stop taking it — but that's the underlying IBS reasserting itself, not withdrawal from the medicine.

Mebeverine is one of the better-tolerated medicines used for IBS, which is much of its appeal. Most people experience no side effects at all. The main reported issue is occasional skin reactions — rash, hives, or, very rarely, more significant hypersensitivity reactions including swelling of the face, lips, or throat (angioedema). These are uncommon but warrant stopping the medicine and seeking medical advice. Beyond that, mebeverine genuinely doesn't have the dry-mouth, blurred-vision, drowsiness, or urinary retention effects that older antispasmodics produce, which is why it's often the first antispasmodic tried in long-term IBS management.

Alcohol doesn't directly interact with mebeverine in the way it interacts with, say, metronidazole. A glass of wine or a beer is unlikely to cause a problem from the medicine itself. The complication is that alcohol is a recognised trigger for IBS symptoms in many people — it can speed gut transit, irritate the gut lining, and disturb the gut microbiome. So while there's no medical reason to abstain entirely, paying attention to whether alcohol seems to bring on your symptoms, and moderating accordingly, is part of sensible IBS management.

The safety data in pregnancy is genuinely limited, and the manufacturer advises caution. Most clinicians prefer to avoid mebeverine during pregnancy unless it's clearly needed and other measures haven't worked, both because data is sparse and because IBS symptoms in pregnancy can often be managed with dietary adjustment, fibre changes, and reassurance. Breastfeeding sits in a similar grey zone — small amounts may pass into breast milk, and again, alternative approaches are usually preferred. If you're pregnant, planning a pregnancy, or breastfeeding and your IBS symptoms are significant, it's worth having a direct conversation with your GP rather than self-managing — there are options that are better studied in these settings.

This is one of mebeverine's quieter advantages: it has very few clinically significant drug interactions. It doesn't meaningfully affect blood thinners, blood pressure medicines, antidepressants, hormonal contraceptives, or most other commonly prescribed drugs. That makes it a good choice for older patients on multiple medications and for anyone with a complex prescription list. As always, it's still worth telling any prescriber that you're taking it, particularly when starting new medicines.

For most people, no — and this is where IBS care has changed significantly in the last decade. The evidence is now strong that dietary and lifestyle measures play at least as big a role as medication in long-term IBS control. The most effective dietary approach for many people is the low-FODMAP diet, developed at Monash University in Australia: a structured elimination and reintroduction of certain fermentable carbohydrates (fructose, lactose, fructans, galactans, polyols) that ferment in the gut and produce gas, distension, and loose stools in IBS-prone individuals. It works best when guided by a dietitian, because done badly it can become unnecessarily restrictive. Beyond diet, regular exercise, attention to sleep, stress management, and — for some people — gut-directed psychological therapies such as cognitive behavioural therapy or hypnotherapy have all been shown to make meaningful differences. Mebeverine is a useful tool for the painful, spasmodic dimension of IBS, but it sits within a broader plan that addresses the whole picture.

Several alternatives exist, and one approach often works where another doesn't. Other antispasmodics include hyoscine butylbromide (Buscopan), alverine citrate (Spasmonal), and peppermint oil capsules (Colpermin or Mintec) — peppermint oil has a small but real evidence base for IBS pain and works on smooth muscle through a different mechanism. For diarrhoea-predominant IBS, loperamide helps slow gut transit. For constipation-predominant IBS, fibre adjustments, isphagula husk (Fybogel), or specific laxatives may be more useful. Low-dose tricyclic antidepressants (such as amitriptyline) and SSRIs are sometimes used not for depression but for their effect on gut-brain signalling and visceral pain — they can be transformative for some people with persistent IBS pain. If mebeverine alone hasn't helped after a fair trial, the next step is usually to broaden the approach rather than just keep increasing the dose.

There are a few situations that require prompt medical review rather than self-management — and they matter, because IBS is what's known as a diagnosis of exclusion, meaning other conditions need to be ruled out first. The features that warrant urgent assessment, often called "red flags", include unintentional weight loss, rectal bleeding or blood in the stool, persistent diarrhoea (especially at night, which IBS doesn't typically cause), iron-deficiency anaemia, a family history of bowel or ovarian cancer, new bowel symptoms starting after age 50, an abdominal or rectal mass, and any markedly worsening symptoms. None of these features fits IBS, and they need investigation to exclude inflammatory bowel disease (Crohn's, ulcerative colitis), coeliac disease, and bowel cancer. Beyond the red flags, a clinical review is also worthwhile if symptoms aren't responding to standard measures, if they're significantly affecting your quality of life, work, or sleep, or if you've never had a formal diagnosis and want one.